Your Health. Your Family. Your Choice.
Life Threatening? No
Write-up: Death unexplained; Oxygen saturation decreased; This is a spontaneous report from a contactable Pharmacist downloaded from the regulatory authority-WEB FR-AFSSAPS-AN20210159. A 86-years-old female patient received the first dose of bnt162b2 (COMIRNATY; Lot # EM0477) vaccine , intramuscular on 12Jan2021 at single dose for Covid-19 immunisation . Medical history included dementia, bedridden . Concomitant medication included benserazide hydrochloride, levodopa (LEVODOPA BENSERAZIDE), potassium chloride (DIFFU K), paracetamol (PARACETAMOL), lactulose (LACTULOSE), glucose (GLUCOSE). The patient experienced death unexplained on 27Jan2021 , oxygen saturation decreased from 25Jan2021 to death. The patient was vaccinated against COVID-19 by a first injection of COMIRNATY on 12Jan2021. No immediate reaction reported after vaccination. No hyperthermia episode. This was a bedridden patient living in a nursing home and who has been eating little since January. The patient''s condition has deteriorated since the end of November 2020. On 19Jan2021, the examination of the patient was very difficult, the patient was also non-dyspneic. On 25Jan2021, it presented a deterioration of the general condition and a desaturation. The patient died of unknown cause on 27Jan2021. An autopsy was not performed. No follow-up attempts are possible, batch number already obtained.; Reported Cause(s) of Death: Death unexplained
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166